Search

Your search keyword '"Luka Culibrk"' showing total 2 results
Start Over Author "Luka Culibrk" Journal nature cancer
2 results on '"Luka Culibrk"'

1. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes

Author

Cameron J. Grisdale, Scott D. Brown, Kevin Y. Fan, Wei Zhang, Caralyn Reisle, Zoltan Bozoky, Robert A. Holt, Tariq Vira, Richard Corbett, Melika Bonakdar, My Linh Thibodeau, Kathleen Wee, Dean Cheng, Luka Culibrk, Marcus Carreira, David F. Schaeffer, Deirdre Weymann, Anna V. Tinker, Eric Y. Zhao, Michael K.C. Lee, Karen A. Gelmon, Karen Mungall, Richard A. Moore, Dean A. Regier, Daniel J. Renouf, Zusheng Zong, Reva Shenwai, Stephen Chia, Jahanshah Ashkani, Ana Fisic, Stephen Yip, Darryl D’Souza, Yussanne Ma, Daniel MacMillan, Erin Pleasance, Steve Bilobram, Alexandra Fok, Amir Muhammadzadeh, Jean-Michel Lavoie, Martin R. Jones, Hillary Pearson, Simon K. Chan, Balvir Deol, Steven J.M. Jones, Andrew J. Mungall, Mya Warren, Gregory A. Taylor, Elisa Majounie, Harwood H. Kwan, Eric Chuah, Howard John Lim, Sara Sadeghi, Dustin Bleile, Emma Titmuss, Reanne Bowlby, Anna Davies, Laura Williamson, Jessica Nelson, Caleb Choo, Jasleen K. Grewal, Katherine Dixon, Yongjun Zhao, Shehara Mendis, Yaoqing Shen, Janessa Laskin, Joanna M. Karasinska, Veronika Csizmok, Tina Wong, Sophie Sun, Kasmintan A. Schrader, and Marco A. Marra

Subjects
Cancer Research, Mutation, DNA repair, medicine.medical_treatment, Cancer, Context (language use), Computational biology, Immunotherapy, Biology, medicine.disease, medicine.disease_cause, Transcriptome, Oncology, medicine, DPYD, Gene
Abstract

Advanced and metastatic tumors with complex treatment histories drive cancer mortality. Here we describe the POG570 cohort, a comprehensive whole-genome, transcriptome and clinical dataset, amenable for exploration of the impacts of therapies on genomic landscapes. Previous exposure to DNA-damaging chemotherapies and mutations affecting DNA repair genes, including POLQ and genes encoding Polζ, were associated with genome-wide, therapy-induced mutagenesis. Exposure to platinum therapies coincided with signatures SBS31 and DSB5 and, when combined with DNA synthesis inhibitors, signature SBS17b. Alterations in ESR1, EGFR, CTNNB1, FGFR1, VEGFA and DPYD were consistent with drug resistance and sensitivity. Recurrent noncoding events were found in regulatory region hotspots of genes including TERT, PLEKHS1, AP2A1 and ADGRG6. Mutation burden and immune signatures corresponded with overall survival and response to immunotherapy. Our data offer a rich resource for investigation of advanced cancers and interpretation of whole-genome and transcriptome sequencing in the context of a cancer clinic. Marra and colleagues describe POG570, a pan-cancer, whole-genome, transcriptome and clinical dataset stressing the molecular interactions in advanced and post-therapy cancer patients.

Published
2020

2. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes

Author

Erin, Pleasance, Emma, Titmuss, Laura, Williamson, Harwood, Kwan, Luka, Culibrk, Eric Y, Zhao, Katherine, Dixon, Kevin, Fan, Reanne, Bowlby, Martin R, Jones, Yaoqing, Shen, Jasleen K, Grewal, Jahanshah, Ashkani, Kathleen, Wee, Cameron J, Grisdale, My Linh, Thibodeau, Zoltan, Bozoky, Hillary, Pearson, Elisa, Majounie, Tariq, Vira, Reva, Shenwai, Karen L, Mungall, Eric, Chuah, Anna, Davies, Mya, Warren, Caralyn, Reisle, Melika, Bonakdar, Gregory A, Taylor, Veronika, Csizmok, Simon K, Chan, Zusheng, Zong, Steve, Bilobram, Amir, Muhammadzadeh, Darryl, D'Souza, Richard D, Corbett, Daniel, MacMillan, Marcus, Carreira, Caleb, Choo, Dustin, Bleile, Sara, Sadeghi, Wei, Zhang, Tina, Wong, Dean, Cheng, Scott D, Brown, Robert A, Holt, Richard A, Moore, Andrew J, Mungall, Yongjun, Zhao, Jessica, Nelson, Alexandra, Fok, Yussanne, Ma, Michael K C, Lee, Jean-Michel, Lavoie, Shehara, Mendis, Joanna M, Karasinska, Balvir, Deol, Ana, Fisic, David F, Schaeffer, Stephen, Yip, Kasmintan, Schrader, Dean A, Regier, Deirdre, Weymann, Stephen, Chia, Karen, Gelmon, Anna, Tinker, Sophie, Sun, Howard, Lim, Daniel J, Renouf, Janessa, Laskin, Steven J M, Jones, and Marco A, Marra

Subjects
Neoplasms, Humans
Abstract

Advanced and metastatic tumors with complex treatment histories drive cancer mortality. Here we describe the POG570 cohort, a comprehensive whole-genome, transcriptome and clinical dataset, amenable for exploration of the impacts of therapies on genomic landscapes. Previous exposure to DNA-damaging chemotherapies and mutations affecting DNA repair genes, including POLQ and genes encoding Polζ, were associated with genome-wide, therapy-induced mutagenesis. Exposure to platinum therapies coincided with signatures SBS31 and DSB5 and, when combined with DNA synthesis inhibitors, signature SBS17b. Alterations in ESR1, EGFR, CTNNB1, FGFR1, VEGFA and DPYD were consistent with drug resistance and sensitivity. Recurrent noncoding events were found in regulatory region hotspots of genes including TERT, PLEKHS1, AP2A1 and ADGRG6. Mutation burden and immune signatures corresponded with overall survival and response to immunotherapy. Our data offer a rich resource for investigation of advanced cancers and interpretation of whole-genome and transcriptome sequencing in the context of a cancer clinic.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results